Glenmark’s Ryaltris ® nasal spray now approved in Europe for the first-line treatment of allergic rhinitis in patients over 12 years of age

• The launch will ensure much-needed access to a novel fixed-dose combination nasal spray for this chronic condition
• This marks Glenmark’s first innovative product approval in the European Union

PUNE: Glenmark Pharmaceuticals Limited, a research-led, global integrated pharmaceutical company, is concluding the final, national phase of its marketing approval application process to enable the launch of its innovative nasal spray in 17 countries in the European Union. Ryaltris® (olopatadine hydrochloride 665 mcg and mometasone furoate 25 mcg), will shortly be available in Austria, Belgium, Czech Republic, Germany, Denmark, Spain, Finland, France, Ireland, Italy, The Netherlands, Norway, Poland, Romania, Slovakia, Sweden, and the UK.

Glenmark will commercialize Ryaltris® on its own in select markets. In some countries such as France, Italy, Spain, and the Balkan region, Menarini Group will lead the commercialization effort, as part of an exclusive licensing agreement signed with Glenmark in 2020. Under the terms of the agreement, Glenmark is responsible for the continued development and regulatory approval of Ryaltris® in these markets, while Menarini will lead the scientific information and commercialization of Ryaltris®, following regulatory approval. Glenmark has received an upfront payment and will additionally receive launch & sales-based milestone payments from Menarini for Ryaltris® sales.

Ryaltris®, developed by Glenmark, is a novel fixed-dose combination nasal spray of an anti-histamine and asteroid, indicated for the treatment of symptoms associated with allergic rhinitis (AR) in patients over 12 years of age. It relieves symptoms of allergic rhinitis, including stuffy nose, runny nose, nasal itching, sneezing, as well as itchy, red, and watery eyes.

Achin Gupta, Executive Vice President, Business Head EMEA-L (Europe, Middle East, Africa, Latam) Glenmark Pharmaceuticals, said, “Despite many treatments being available for allergic rhinitis, Glenmark is excited to launch Ryaltris® as the only first line combination inhaler treatment option for patients across Europe. Upwards of 25% of the population in Europe suffers from the debilitating symptoms of allergic rhinitis, so we hope that Ryaltris® will bring some of these real benefits – a simple inhaler, offering fast and effective relief.”   

Glenmark has also partnered with Hikma Pharmaceuticals PLC and Bausch Health for the commercialisation of Ryaltris® in the US and Canada respectively. Ryaltris® sales continue to progress well in Australia, after the successful launch in 2020 by Glenmark’s partner, Seqirus Pty. Ltd. Ryaltris® was also recently launched in South Africa, Ukraine and Uzbekistan. So far, Glenmark has received approval for Ryaltris® in Australia, South Korea, Cambodia, Ukraine, Uzbekistan, Namibia, Russia, South Africa, and Ecuador. Ryaltris® is currently under regulatory review in Canada, Brazil, Malaysia, Saudi Arabia and several other markets. Glenmark’s partner in China, Grand Pharmaceutical (China) Co. Ltd., plans to submit an IND in this financial year.  

source https://nrinews24x7.com/glenmarks-ryaltris-nasal-spray-now-approved-in-europe-for-the-first-line-treatment-of-allergic-rhinitis-in-patients-over-12-years-of-age/?utm_source=rss&utm_medium=rss&utm_campaign=glenmarks-ryaltris-nasal-spray-now-approved-in-europe-for-the-first-line-treatment-of-allergic-rhinitis-in-patients-over-12-years-of-age

April 30, 2021